How to Improve Chondrosarcoma Treatment? From Fundamental Research to Biomarker Discovery and Clinical Applications
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (15 December 2023) | Viewed by 2707
Special Issue Editor
Interests: cancer cell biology; chondrosarcoma; DNA damage response; signaling transduction; radiation-induced bystander effects; tumor cell radiosensitization; proteomics; radiation response biomarkers; radioresistance; tumor microenvironment; inflammatory
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Chondrosarcomas belong to a heterogeneous group of tumors that produce a cartilaginous matrix, and are the second most common bone disease in humans, representing 25% of bone neoplasms. Chondrosarcomas are historically classified as conventional (85%), and can be classified as central or peripheral. Most uncommon chondrosarcomas involving low- and middle-grade tumors develop slowly, with low metastatic potential. However, 5–10% of chondrosarcomas are advanced, and these includes mesenchymal and dedifferentiated chondrosarcomas as well as a subset of normal chondrosarcomas that has high metastatic prognosis and carries a bad prognosis.Clinical research on chondrosarcomas focuses on new noninvasive treatments and chemotherapy–refractory or metastatic chondrosarcomas. Although many types of cancer have many novel treatment options, chondrosarcomas have no effective treatment without surgery and continue to be associated with adverse clinical outcomes.
Recent research has suggested a few promising biomarkers and therapeutic targets for chondrosarcomas. Several molecular-targeting agents and innovative therapies have shown good antitumor activity in clinical studies in patients with advanced chondrosarcomas.
The main topics of this Special Issue are related to the latest basic studies on biomarkers and molecular targets, as well as the most recent clinical studies on the treatment of chondrosarcomas.
I am pleased to invite you to contribute to this Special Issue with research papers, up-to-date review articles, and commentaries.
Dr. François Chevalier
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- chondrosarcoma
- biomarkers
- innovative therapy
- therapeutic target
- clinical studies
